Abstract
A novel triazole nucleoside analogue was discovered to exhibit potent anticancer activity in prostate cancer cells via down-regulating heat shock factor 1 (HSF1) and related heat shock proteins, along with the consequential inhibition of androgen receptor (AR) expression and transactivation, arresting the cell cycle in AR-governed phase. This triazole nucleoside therefore constitutes a novel structural paradigm and potential drug candidate for prostate cancer through inhibition of HSF1 and AR.
Keywords: Androgen receptor, anticancer activity, heat shock proteins, heat shock factor 1, nucleoside analogues, prostate cancer.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor
Volume: 15 Issue: 10
Author(s): Yi Xia, Menghua Wang, Eliana Beraldi, Mei Cong, Amina Zoubeidi, Martin Gleave and Ling Peng
Affiliation:
Keywords: Androgen receptor, anticancer activity, heat shock proteins, heat shock factor 1, nucleoside analogues, prostate cancer.
Abstract: A novel triazole nucleoside analogue was discovered to exhibit potent anticancer activity in prostate cancer cells via down-regulating heat shock factor 1 (HSF1) and related heat shock proteins, along with the consequential inhibition of androgen receptor (AR) expression and transactivation, arresting the cell cycle in AR-governed phase. This triazole nucleoside therefore constitutes a novel structural paradigm and potential drug candidate for prostate cancer through inhibition of HSF1 and AR.
Export Options
About this article
Cite this article as:
Xia Yi, Wang Menghua, Beraldi Eliana, Cong Mei, Zoubeidi Amina, Gleave Martin and Peng Ling, A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/1871520615666150617110943
DOI https://dx.doi.org/10.2174/1871520615666150617110943 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of Development and Formulation of <sup>177</sup>Lu-DOTA-TATE for PRRT
Current Radiopharmaceuticals Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Commentary: Intravenous Immunoglobulin (IVIG) Therapy for Patients with Langerhans Cell Histiocytosis (LCH)-Related Neurodegenerative Diseases of the CNS
CNS & Neurological Disorders - Drug Targets Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design Update on Screening in Prostate Cancer Based on Recent Clinical Trials
Reviews on Recent Clinical Trials Neuropeptidomics: Improvements in Mass Spectrometry Imaging Analysis and Recent Advancements
Current Protein & Peptide Science Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design HUHS1015 Induces Necroptosis and Caspase-Independent Apoptosis of MKN28 Human Gastric Cancer Cells in Association with AMID Accumulation in the Nucleus
Anti-Cancer Agents in Medicinal Chemistry Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis
Current Pharmaceutical Design Targeted Alpha Therapy with 213Bi
Current Radiopharmaceuticals Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Meet Our Editorial Board Member
Current Cancer Drug Targets Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia
Current Molecular Medicine